Lorlatinib serves as an ATP-competitive TKI for both ALK and ROS1, an RTK in the insulin receptor family with striking similarity to ALK that is overexpressed in several cancer types, but absent in normal lung tissue. This evidence concerns the gene ALK and cancer.